Back HIV/AIDS HIV/AIDS Topics HIV Treatment

Studies Reveal Age, Race, and Sex Disparities in HIV Care and Outcomes

Women, African-Americans, and people who inject drugs are on average less likely to remain in care,start antiretroviral therapy (ART), or achieve viral load suppression, while young people are more likely to seek HIV care later in the course of their disease, according to 2 recently published studies.

alt

Read more:

Updated Guidelines for Antiretroviral Treatment of Children with HIV

The Department of Health and Human Services this week updated its Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Changes to the children's guidelines include specific drug recommendations and information about a possible cure of an HIV-infected infant following very early treatment.

alt

Read more:

Low Drug Levels in Lymphatic Tissue May Underlie Low HIV Viral Load

HIV continues to replicate in the lymph nodes of people taking antiretroviral therapy (ART) that suppresses viral load in peripheral blood, according to a small study in the January 27 early online edition of Proceedings of the National Academy of Sciences. Several commonly used antiretroviral drugs reached lower concentrations in lymphatic tissue compared with blood, allowing ongoing virus production that may contribute to increased inflammation and immune activation in people with apparently well-controlled HIV.

alt

Read more:

HIV Regimens with Fewer Pills Promote Adherence and Viral Suppression

Antiretroviral regimens that contain fewer pills are associated with improvement in treatment adherence and higher likelihood of achieving undetectable viral load, according to a meta-analysis published in the January 22, 2014, advance edition of Clinical Infectious Diseases. Once-daily dosing however, had only a modest effect on adherence and did not significant impact viral suppression.

alt

Read more:

Highlights from 2013 ICAAC, IDWeek, and EACS Meetings

Latest Positive Pulse Newsletter

In this overview Paul Sax from Harvard Medical School and Mark Sulkowski from Johns Hopkins discuss selected highlights from this fall's Interscience Conference on Microbial Agents and Chemotherapy (ICAAC), IDWeek, and the European AIDS Conference. The newsletter is available to all for free, with continuing medical education (CME) credit available for physicians and nurses.alt

Read more:

amFAR Announces Initiative to Find Cure for HIV by 2020

This week amfAR, the Foundation for AIDS Research, launched a new research initiative, Countdown to a Cure for HIV/AIDS, with the goal of finding a broadly applicable cure for HIV/AIDS by the year 2020.The foundation hopes to raise $100 million to support this effort.

alt

Read more:

Dolutegravir for HIV and Sofosbuvir for Hepatitis C Approved in Europe

The European Commission this week approved 2 important new drugs, ViiV Healthcare's HIV integrase inhibitor dolutegravir (brand name Tivicay) and Gilead Science's nucleotide hepatitis C virus polymerase inhibitor sofosbuvir (Sovaldi).

alt

Read more: